Molecular cloning of a brain-specific, developmentally regulated neuregulin 1 (NRG1) isoform and identification of a functional promoter variant associated with schizophrenia - PubMed (original) (raw)
. 2007 Aug 17;282(33):24343-51.
doi: 10.1074/jbc.M702953200. Epub 2007 Jun 12.
Affiliations
- PMID: 17565985
- DOI: 10.1074/jbc.M702953200
Free article
Molecular cloning of a brain-specific, developmentally regulated neuregulin 1 (NRG1) isoform and identification of a functional promoter variant associated with schizophrenia
Wei Tan et al. J Biol Chem. 2007.
Free article
Abstract
Neuregulin 1 (NRG1) is essential for the development and function of multiple organ systems, and its dysregulation has been linked to diseases such as cancer and schizophrenia. Recently, altered expression of a novel isoform (type IV) in the brain has been associated with schizophrenia-related genetic variants, especially rs6994992 (SNP8NRG243177). Here we have isolated and characterized full-length NRG1 type IV cDNAs from the adult and fetal human brain and identified novel splice variants of NRG1. Full-length type IV spans 1.8 kb and encodes a putative protein of 590 amino acids with a predicted molecular mass of approximately 66 kDa. The transcript consists of 11 exons with an Ig-like domain, an epidermal growth factor-like (EGF) domain, a beta-stalk, a transmembrane domain, and a cytoplasmic "a-tail," placing it in the beta1a NRG1 subclass. NRG1 type IV was not detected in any tissues except brain and a putative type IV NRG1 protein of 66 kDa was similarly brain-specific. Type IV transcripts are more abundantly expressed in the fetal brain, where, in addition to the full-length structure, two novel type IV variants were identified. In vitro luciferase-reporter assays demonstrate that the 5' promoter region upstream of type IV is functional, with differential activity associated with genetic variation at rs6994992, and that promoter competition may impact on type IV expression. Our data suggest that type IV is a unique brain-specific NRG1 that is differentially expressed and processed during early development, is translated, and its expression regulated by a schizophrenia risk-associated functional promoter or single nucleotide polymorphism (SNP).
Similar articles
- Molecular and cellular characterization of Neuregulin-1 type IV isoforms.
Shamir A, Buonanno A. Shamir A, et al. J Neurochem. 2010 Jun;113(5):1163-76. doi: 10.1111/j.1471-4159.2010.06677.x. Epub 2010 Mar 10. J Neurochem. 2010. PMID: 20218976 Free PMC article. - Effects of schizophrenia risk variation in the NRG1 gene on NRG1-IV splicing during fetal and early postnatal human neocortical development.
Paterson C, Wang Y, Kleinman JE, Law AJ. Paterson C, et al. Am J Psychiatry. 2014 Sep;171(9):979-89. doi: 10.1176/appi.ajp.2014.13111518. Am J Psychiatry. 2014. PMID: 24935406 Free PMC article. - Lack of association to a NRG1 missense polymorphism in schizophrenia or bipolar disorder in a Costa Rican population.
Moon E, Rollins B, Mesén A, Sequeira A, Myers RM, Akil H, Watson SJ, Barchas J, Jones EG, Schatzberg A, Bunney WE, DeLisi LE, Byerley W, Vawter MP. Moon E, et al. Schizophr Res. 2011 Sep;131(1-3):52-7. doi: 10.1016/j.schres.2011.06.024. Epub 2011 Jul 13. Schizophr Res. 2011. PMID: 21745728 Free PMC article. - Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology.
Harrison PJ, Law AJ. Harrison PJ, et al. Biol Psychiatry. 2006 Jul 15;60(2):132-40. doi: 10.1016/j.biopsych.2005.11.002. Epub 2006 Jan 25. Biol Psychiatry. 2006. PMID: 16442083 Review. - Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies.
Schmitt A, Parlapani E, Gruber O, Wobrock T, Falkai P. Schmitt A, et al. Eur Arch Psychiatry Clin Neurosci. 2008 Nov;258 Suppl 5:35-9. doi: 10.1007/s00406-008-5019-x. Eur Arch Psychiatry Clin Neurosci. 2008. PMID: 18985292 Review.
Cited by
- Effects of Anti-Seizure Medication on Neuregulin-1 Gene and Protein in Patients with First-Episode Focal Epilepsy.
Zhao X, Huang G, Xie Z, Mo Y, Zhu H, Gao Y, Han Y, Tang W. Zhao X, et al. Neuropsychiatr Dis Treat. 2024 Apr 8;20:837-844. doi: 10.2147/NDT.S438942. eCollection 2024. Neuropsychiatr Dis Treat. 2024. PMID: 38618155 Free PMC article. - Gene Polymorphisms and Expression of NRG1, DAOA, and DISC1 Genes in a Chinese Han Population with an Ultra-High Risk for Psychosis.
He XY, Huang ZH, Wang F, Chen ZL, Wang SB, Jia FJ, Hou CL. He XY, et al. Neuropsychiatr Dis Treat. 2023 Nov 21;19:2521-2533. doi: 10.2147/NDT.S434856. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 38029052 Free PMC article. - Schizophrenia-associated NRXN1 deletions induce developmental-timing- and cell-type-specific vulnerabilities in human brain organoids.
Sebastian R, Jin K, Pavon N, Bansal R, Potter A, Song Y, Babu J, Gabriel R, Sun Y, Aronow B, Pak C. Sebastian R, et al. Nat Commun. 2023 Jun 24;14(1):3770. doi: 10.1038/s41467-023-39420-6. Nat Commun. 2023. PMID: 37355690 Free PMC article. - Investigation on substrate specificity and catalytic activity of serine protease neuropsin.
Lintuluoto M, Abe M, Horioka Y, Fukunishi Y, Tamura H, M Lintuluoto J. Lintuluoto M, et al. Biophys Physicobiol. 2022 Sep 22;19:e190040. doi: 10.2142/biophysico.bppb-v19.0040. eCollection 2022. Biophys Physicobiol. 2022. PMID: 36349321 Free PMC article. - Effects of psychosis-associated genetic markers on brain volumetry: a systematic review of replicated findings and an independent validation.
Vouga Ribeiro N, Tavares V, Bramon E, Toulopoulou T, Valli I, Shergill S, Murray R, Prata D. Vouga Ribeiro N, et al. Psychol Med. 2022 Sep 28;52(16):1-16. doi: 10.1017/S0033291722002896. Online ahead of print. Psychol Med. 2022. PMID: 36168994 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases